Shuttle Pharmaceuticals Holdings, Inc. files regulatory reports that document its clinical-stage pharmaceutical business, Molecule.ai software platform, capital structure and governance. Registration statements and related amendments describe securities offered by the company, risk factors, use-of-proceeds disclosures and security terms, including common stock and pre-funded warrant structures.
Its 8-K reports record material agreements, public-offering activity, preliminary operating results and executive or consulting arrangements. Proxy materials cover annual meeting matters such as director elections, auditor ratification, executive-compensation votes and charter-authority proposals.
Shuttle Pharmaceuticals (SHPH) disclosed two material updates. On October 20, 2025, the company signed a binding term sheet to purchase substantially all assets and liabilities of 1542770 BC Ltd. (Molecule) for $10,000,000, payable over time in a mix of cash and SHPH common stock at the company’s determination and tied to milestones. Closing remains subject to definitive agreements, board approval, and due diligence.
Separately, on October 15, 2025, Theradex Systems, the company’s primary CRO, delivered a notice terminating the 2018 master agreement and demanding immediate payment of $1.091 million. The letter cites a contract provision allowing termination for material breach and states Services will cease if payment is not made within 30 days of the letter. Together, the prospective acquisition outlines a strategic transaction, while the CRO action introduces operational and payment pressure until resolved.
Shuttle Pharmaceuticals Holdings, Inc. entered into a material consulting agreement with IR Agency LLC on September 15, 2025. IR Agency will provide marketing and advertising services to communicate information about the company to the financial community, including creating company profiles, distributing media, and building a digital community around the company.
As consideration for these services, the company paid IR Agency $1,450,000 for a two‑month term. The full consulting agreement is referenced as an exhibit to the report.
Shuttle Pharmaceuticals Holdings, Inc. reported changes to its board leadership. On September 12, 2025, Sachin Pathigoda and Angel Liriano were appointed as directors. On September 15, 2025, Mr. Pathigoda became Chairman of the Nominating and Corporate Governance Committee and joined the Audit Committee, while Mr. Liriano became Chairman of the Compensation Committee and joined the Nominating and Corporate Governance Committee. The company also named existing director George Scorsis as Chairman of the Audit Committee. The filing notes there are no family relationships with current directors or executive officers, no related-party transactions requiring disclosure, and no special arrangements or understandings behind the new director appointments.
Shuttle Pharmaceuticals Holdings, Inc. reported that on September 11, 2025, director Joseph Tung resigned from its board of directors. The company stated that Mr. Tung’s resignation was not the result of any disagreement that would require disclosure under the relevant SEC rules, indicating it was not tied to a reportable dispute over company operations, policies, or practices.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed an initial Form 3 reporting that Adam V. Chambers is a director as of 09/08/2025. The filing lists Mr. Chambers' business address in Gaithersburg, MD and indicates he directly beneficially owns 0 shares of the issuer's common stock and holds no derivative securities. The form is an initial disclosure of a director's ownership and contains no reported holdings or exercisable awards.
Shuttle Pharmaceuticals Holdings, Inc. reported that its Board of Directors appointed Adam Chambers as a director effective September 8, 2025. Mr. Chambers is the principal of Bowery Consulting Group Inc., which is the lender under the Company’s revolving loan agreement dated February 28, 2025, and also a party to a consulting services agreement dated March 21, 2025. The Company states there are no family relationships between Mr. Chambers and any of its directors or executive officers, and, other than the loan and consulting agreements, he has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K. The filing also notes there were no arrangements or understandings by which he was appointed to the Board.
Shuttle Pharmaceuticals Holdings, Inc. reported that Steven Richards resigned as a director of the company on August 31, 2025. The company stated that Mr. Richards’ resignation was not due to any disagreements with Shuttle Pharmaceuticals regarding its operations, policies, or practices. The report was signed on behalf of the company by Interim Chief Executive Officer Christopher Cooper.
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G reporting shared beneficial ownership of 56,237 shares of Shuttle Pharmaceuticals Holdings, Inc. common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and pursuant to an investment management agreement exercises voting and investment power over those securities. Mr. Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control.
Steven M. Richards, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 Restricted Stock Units (RSUs) on 08/08/2025, as reported on a Form 4 signed 08/12/2025. The filing states each RSU represents the contingent right to receive one share of common stock at no cash price.
One-third of the RSUs will vest on each of 08/08/2026, 08/08/2027 and 08/08/2028, meaning the award converts into a total of 29,240 shares if all vest according to the stated schedule. The Form 4 lists the ownership form as direct and shows the grant was reported under a non-cash equity award.
Shuttle Pharmaceuticals director Oleh Nabyt was granted 29,240 restricted stock units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock and is reported with a $0 price. The RSUs vest in three equal installments: one-third on 08/08/2026, one-third on 08/08/2027 and one-third on 08/08/2028. The award is reported as a direct beneficial holding and, if fully vested and converted, would result in receipt of up to 29,240 shares of common stock.